Oligonucleotide Synthesis Market by Product & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical & Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global Forecast to 2019

世界のオリゴヌクレオチド合成市場:オリゴ合成装置、試薬、サービス

◆タイトル:Oligonucleotide Synthesis Market by Product & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical & Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global Forecast to 2019
◆商品コード:MAM-BT-2680
◆調査・発行会社:MarketsandMarkets
◆発行日:2014年8月
◆ページ数:168
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:バイオ
◆販売価格オプション(消費税別)
Single UserUSD5,650 ⇒換算¥621,500見積依頼/購入/質問フォーム
Site LicenseUSD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate LicenseUSD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"世界のオリゴヌクレオチド合成市場:オリゴ合成装置、試薬、サービス"について調査・分析し、イントロダクション、エグゼクティブサマリー、プレミアムインサイト、市場概観、市場の成長要因、阻害要因、市場の機会と課題、産業動向、サプライチェーン分析、市場環境分析、市場の動態、製品別分析、サービス別分析、用途別分析、需要先別分析、市場規模及び予測、競争状況、新製品発売、主要企業(ベンダー)分析等の情報をお届けいたします。

The global oligonucleotide synthesis market is expected to reach $1,712.1 million by 2019 from $1,070.7 million in 2014, growing at a CAGR of 9.8% from 2014 to 2019. The global oligonucleotide synthesis market is categorized on the basis of products and services, applications, end users, and geography. The synthesized oligonucleotides segment is expected to register the highest growth rate in the oligonucleotide synthesis market during the forecast period, owing to an increasing number of applications for synthesized oligonucleotides in research, diagnostics and therapeutics; and a growing demand for custom oligos.

Major factors contributing to growth of the oligonucleotide synthesis market include growing R&D expenditure in pharmaceutical and biotech companies; emerging applications of oligos in molecular diagnostics and synthetic biology; and evolving significance of RNA-interference oligos in therapeutics and diagnostics. Furthermore, government support and venture capital funding are other major factors that will boost the growth of this market. For instance, the U.S. National Institutes of Health (NIH) spend $1.5 billion per year to support their oligonucleotide-based applications. Further, in January 2013, Solstice Biologics, a South California start-up, raised $18 million in a series-A financing backed by venture capital funding for targeting and delivery of nucleic acid therapeutics. The relatively-untapped markets of the Asia-Pacific (APAC) region and the increasing R&D activities and funding there have opened up an array of opportunities for the oligonucleotide synthesis market. However, factors such as regulatory barriers, especially for therapeutic oligos, and downward pricing pressure may restrain the growth of this market.

Apart from the comprehensive geographic and product analysis, and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by players in the industry over the last three years. In addition, the company profiles comprise the key players in the oligonucleotide synthesis market and their product portfolios, developments, and strategies. The above-mentioned market research data, current market size, and forecast of future trends will help key players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, R&D investments for innovations in products and technologies, and levels of output, in order to remain successful.

Reasons to Buy the Report:

The report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help the firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on product portfolios of the top players in the oligonucleotide synthesis market. The report analyzes the oligonucleotide synthesis market by products and services, applications, end users, and geography
• Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and new product launches in the oligonucleotide synthesis market
• Competitive Assessment: In-depth assessment of the market strategies, geographical and business segments, and product portfolios of the leading players in the oligonucleotide synthesis market
• Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the market for various oligonucleotide synthesis products across geographies
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the oligonucleotide synthesis market

【レポートの目次】

TABLE OF CONTENTS

1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKETS COVERED 19
1.3 STAKEHOLDERS 20
1.4 MARKET SCOPE 20
2 RESEARCH METHODOLOGY 21
2.1 MARKET SIZE ESTIMATION 22
2.2 MARKET CRACKDOWN & DATA TRIANGULATION 24
2.3 KEY DATA FROM SECONDARY SOURCES 24
2.4 KEY DATA FROM PRIMARY SOURCES 25
2.5 KEY INDUSTRY INSIGHTS 26
2.6 ASSUMPTIONS 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 30
4.1 ATTRACTIVE MARKET OPPORTUNITIES IN THE SYNTHESIZED OLIGONUCLEOTIDES MARKET 30
4.2 OLIGONUCLEOTIDE SYNTHESIS MARKET IN THE ASIA-PACIFIC REGION 31
4.3 U.S. COMMANDS NEARLY HALF OF THE MARKET SHARE 32
4.4 GEOGRAPHIC REVIEW OF THE OLIGONUCLEOTIDE SYNTHESIS MARKET 32
4.5 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: PCR SEGMENT (2019) 33
4.6 SIGNIFICANT CONTRIBUTION OF SYNTHESIZED OLIGONUCLEOTIDES TO THE TOTAL MARKET GROWTH FROM 2014–2019 34
4.7 LIFE CYCLE ANALYSIS, BY GEOGRAPHY 35
5 MARKET OVERVIEW 36
5.1 INTRODUCTION 37
5.2 MARKET SEGMENTATION 37
5.2.1 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCTS & SERVICES 37
5.2.2 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 38
5.2.3 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 38
5.3 MARKET DYNAMICS 39
5.3.1 DRIVERS 40
5.3.1.1 Increasing R&D expenditure in pharmaceutical and biotechnology companies to boost the synthetic oligonucleotides (oligos) market 40
5.3.1.2 Rising demand from researchers owing to the growing molecular biology field is driving the market growth 40
5.3.1.3 Increasing significance of personalized medicine, companion diagnostics, and molecular diagnostics driving the market growth 40
5.3.1.4 Continuous innovations in genomics technologies & presence of favorable government support to boost market growth 41
5.3.1.5 Increasing demand for synthetic genes is propelling the demand for oligos 41
5.3.2 RESTRAINTS 42
5.3.2.1 Continuous downward price pressure posing as a major market growth barrier 42
5.3.2.2 Regulatory challenges opposing the market growth, especially for therapeutic oligos 43
5.3.3 OPPORTUNITIES 44
5.3.3.1 Asian market presents significant growth opportunities 44
5.3.3.2 Emerging field of NGS to boost demand for NGS-grade oligos 44
5.3.4 CHALLENGES 45
5.3.4.1 Large-scale synthesis of oligonucleotides 45
5.3.4.2 Manufacturing high-quality RNA oligos 46
5.4 LEADING MARKET PLAYERS 46
5.4.1 EQUIPMENT MARKET 46
5.4.2 REAGENTS MARKET 47
5.4.3 SYNTHESIZED OLIGONUCLEOTIDES MARKET 48
6 INDUSTRY TRENDS 49
6.1 INTRODUCTION 49
6.1.1 INDUSTRY TRENDS 49
6.2 PORTER’S FIVE FORCES ANALYSIS 50
6.2.1 THREAT FROM NEW ENTRANTS 50
6.2.2 THREAT FROM SUBSTITUTES 51
6.2.3 BARGAINING POWER OF SUPPLIERS 51
6.2.4 BARGAINING POWER OF BUYERS 51
6.2.5 INTENSITY OF COMPETITIVE RIVALRY 51
6.3 PEST ANALYSIS 52
6.3.1 POLITICAL FACTORS 52
6.3.2 ECONOMIC FACTORS 52
6.3.3 SOCIAL FACTORS 53
6.3.4 TECHNOLOGICAL FACTORS 53
6.4 SUPPLY CHAIN ANALYSIS 53
6.4.1 KEY INFLUENCERS 54
7 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCTS & SERVICES 55
7.1 INTRODUCTION 56
7.2 SYNTHESIZED OLIGONUCLEOTIDES 58
7.2.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT 59
7.2.1.1 Primers 60
7.2.1.2 Probes 61
7.2.1.3 Large-scale Synthesis Oligos 62
7.2.1.4 Intermediate-scale Synthesis Oligos 63
7.2.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY SERVICE 64
7.2.2.1 Custom Oligos 65
7.2.2.2 Predesigned Oligos 66
7.3 REAGENTS 67
7.4 EQUIPMENT 69
8 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 72
8.1 INTRODUCTION 73
8.2 RESEARCH 74
8.2.1 PCR 76
8.2.2 QPCR 77
8.2.3 SEQUENCING 78
8.2.4 GENE SYNTHESIS 79
8.2.5 OTHER RESEARCH APPLICATIONS 81
8.3 DIAGNOSTICS 82
8.4 THERAPEUTICS 83
8.4.1 DNA/ANTISENSE OLIGOS 85
8.4.2 RNAI 86
8.4.3 NUCLEIC ACID APTAMERS 87
8.4.4 OTHER THERAPEUTIC APPLICATIONS 87
9 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 89
9.1 INTRODUCTION 90
9.2 ACADEMIC RESEARCH INSTITUTES 91
9.3 DIAGNOSTIC LABORATORIES 93
9.4 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 94
9.5 OTHERS 95
10 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET, BY GEOGRAPHY 96
10.1 INTRODUCTION 97
10.2 NORTH AMERICA 98
10.2.1 U.S. 103
10.2.2 CANADA 104
10.3 EUROPE 105
10.4 ASIA-PACIFIC (APAC) 108
10.5 LATIN AMERICA 114
10.6 MIDDLE EAST & AFRICA 117
11 COMPETITIVE LANDSCAPE 121
11.1 OVERVIEW 121
11.2 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS, & JOINT VENTURES 124
11.3 EXPANSIONS 125
11.4 NEW PRODUCT LAUNCHES 126
11.5 MERGERS & ACQUISITIONS 127
11.6 OTHER DEVELOPMENTS 128
12 COMPANY PROFILES 129
12.1 BIOAUTOMATION CORPORATION 129
12.2 GE HEALTHCARE (A SUBSIDIARY OF GENERAL ELECTRIC COMPANY) 132
12.3 INTEGRATED DNA TECHNOLOGIES 135
12.4 SIGMA-ALDRICH CORPORATION 139
12.5 THERMO FISHER SCIENTIFIC, INC. 144
12.6 BIOSEARCH TECHNOLOGIES, INC. 149
12.7 EUROFINS GENOMICS (A SUBSIDIARY OF EUROFINS SCIENTIFIC GROUP) 153
12.8 EUROGENTEC (A SUBSIDIARY OF KANEKA CORPORATION) 156
12.9 GENEDESIGN, INC. 159
12.10 TRILINK BIOTECHNOLOGIES, INC. 160
*Details on Business Overview, Financial, Product Portfolio, Key Strategy, & Recent Developments might not be captured in case of unlisted companies.

13 APPENDIX 163
13.1 DISCUSSION GUIDE 163
13.2 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 165
13.3 AVAILABLE CUSTOMIZATIONS 166
13.4 RELATED REPORTS 167

LIST OF TABLES

TABLE 1 INCREASING R&D EXPENDITURE IN PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES PROPELLING THE OLIGONUCLEOTIDE SYNTHESIS MARKET GROWTH 42
TABLE 2 REGULATORY BARRIERS & DOWNWARD PRICING PRESSURE ARE THE MAJOR FACTORS RESTRAINING THE MARKET GROWTH 44
TABLE 3 EMERGING ASIA-PACIFIC MARKETS ARE PAVING NEW GROWTH AVENUES FOR PLAYERS IN THE OLIGONUCLEOTIDE SYNTHESIS MARKET 45
TABLE 4 MANUFACTURING HIGH-QUALITY RNA OLIGOS IS A MAJOR MARKET CHALLENGE 46
TABLE 5 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION) 57
TABLE 6 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GEOGRAPHY,
2012–2019 ($MILLION) 58
TABLE 7 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY GEOGRAPHY,
2012–2019 ($MILLION) 59
TABLE 8 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY COUNTRY,
2012–2019 ($MILLION) 59
TABLE 9 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 60
TABLE 10 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE FOR PRIMERS,
BY GEOGRAPHY, 2012–2019 ($MILLION) 61
TABLE 11 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE FOR PROBES,
BY GEOGRAPHY, 2012–2019 ($MILLION) 62
TABLE 12 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE FOR LARGE-SCALE SYNTHESIS OLIGOS, BY GEOGRAPHY, 2012–2019 ($MILLION) 63
TABLE 13 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE FOR INTERMEDIATE-SCALE SYNTHESIS OLIGOS, BY GEOGRAPHY, 2012–2019 ($MILLION) 64
TABLE 14 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY SERVICE,
2012–2019 ($MILLION) 65
TABLE 15 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE FOR CUSTOM OLIGOS,
BY GEOGRAPHY, 2012–2019 ($MILLION) 66
TABLE 16 GLOBAL SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE FOR PREDESIGNED OLIGOS, BY GEOGRAPHY, 2012–2019 ($MILLION) 67
TABLE 17 GLOBAL OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET SIZE,
BY GEOGRAPHY, 2012–2019 ($MILLION) 68
TABLE 18 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS REAGENTS MARKET SIZE,
BY COUNTRY, 2012–2019 ($MILLION) 69
TABLE 19 GLOBAL OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET SIZE,
BY GEOGRAPHY, 2012–2019 ($MILLION) 70
TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET SIZE,
BY COUNTRY, 2012–2019 ($MILLION) 71
TABLE 21 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 74
TABLE 22 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR RESEARCH APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 75
TABLE 23 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR RESEARCH APPLICATIONS, BY TECHNOLOGY, 2012–2019 ($MILLION) 76
TABLE 24 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR PCR RESEARCH APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 77
TABLE 25 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR QPCR RESEARCH APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 78
TABLE 26 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR SEQUENCING RESEARCH APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 79
TABLE 27 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR GENE SYNTHESIS RESEARCH APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 80
TABLE 28 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR OTHER RESEARCH APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 81
TABLE 29 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR DIAGNOSTIC APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 82
TABLE 30 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 83
TABLE 31 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TECHNOLOGY, 2012–2019 ($MILLION) 85
TABLE 32 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR DNA/ANTISENSE OLIGOS THERAPEUTIC APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 85
TABLE 33 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR RNAI THERAPEUTIC APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 86
TABLE 34 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR NUCLEIC ACID APTAMERS, BY GEOGRAPHY, 2012–2019 ($MILLION) 87
TABLE 35 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR OTHER THERAPEUTIC APPLICATIONS, BY GEOGRAPHY, 2012–2019 ($MILLION) 88
TABLE 36 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 90
TABLE 37 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR ACADEMIC RESEARCH INSTITUTES, BY GEOGRAPHY, 2012–2019 ($MILLION) 92
TABLE 38 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR DIAGNOSTIC LABORATORIES, BY GEOGRAPHY, 2012–2019 ($MILLION) 94
TABLE 39 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY GEOGRAPHY, 2012–2019 ($MILLION) 94
TABLE 40 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OTHER END USERS,
BY GEOGRAPHY, 2012–2019 ($MILLION) 95
TABLE 41 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY GEOGRAPHY,
2012–2019 ($MILLION) 97
TABLE 42 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY COUNTRY,
2012–2019 ($MILLION) 100
TABLE 43 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION) 100
TABLE 44 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 100
TABLE 45 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY SERVICE,
2012–2019 ($MILLION) 101
TABLE 46 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 101
TABLE 47 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR RESEARCH APPLICATIONS, BY TYPE, 2012–2019 ($MILLION) 102
TABLE 48 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2012–2019 ($MILLION) 102
TABLE 49 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END USER, 2012–2019 ($MILLION) 103
TABLE 50 U.S.: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION) 103
TABLE 51 CANADA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION) 104
TABLE 52 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION) 106
TABLE 53 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 106
TABLE 54 EUROPE: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY SERVICE,
2012–2019 ($ MILLION) 106
TABLE 55 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 107
TABLE 56 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR RESEARCH APPLICATIONS, BY TYPE, 2012–2019 ($MILLION) 107
TABLE 57 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2012–2019 ($MILLION) 108
TABLE 58 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 108
TABLE 59 ASIA-PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION) 110
TABLE 60 ASIA-PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY PRODUCT,
2012–2019 ($MILLION) 111
TABLE 61 ASIA-PACIFIC: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY SERVICE,
2012–2019 ($MILLION) 111
TABLE 62 ASIA-PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 112
TABLE 63 ASIA-PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR RESEARCH APPLICATIONS, BY TYPE, 2012–2019 ($MILLION) 112
TABLE 64 ASIA-PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2012–2019 ($MILLION) 113
TABLE 65 ASIA-PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 113
TABLE 66 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY PRODUCTS & SERVICES, 2012–2019 ($MILLION) 114
TABLE 67 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY PRODUCT, 2012–2019 ($MILLION) 115
TABLE 68 LATIN AMERICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE, BY SERVICE,
2012–2019 ($MILLION) 115
TABLE 69 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION,
2012–2019 ($MILLION) 115
TABLE 70 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR RESEARCH APPLICATIONS, BY TYPE, 2012–2019 ($MILLION) 116
TABLE 71 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2012–2019 ($MILLION) 116
TABLE 72 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY END USER,
2012–2019 ($MILLION) 117
TABLE 73 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE,
BY PRODUCTS & SERVICES, 2012–2019 ($MILLION) 118
TABLE 74 MIDDLE EAST & AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE,
BY PRODUCT, 2012–2019 ($MILLION) 118
TABLE 75 MIDDLE EAST & AFRICA: SYNTHESIZED OLIGONUCLEOTIDES MARKET SIZE,
BY SERVICE, 2012–2019 ($MILLION) 118
TABLE 76 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE,
BY APPLICATION, 2012–2019 ($MILLION) 119
TABLE 77 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR RESEARCH APPLICATIONS, BY TYPE, 2012–2019 ($MILLION) 119
TABLE 78 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2012–2019 ($MILLION) 120
TABLE 79 MIDDLE EAST & AFRICA: OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE,
BY END USER, 2012–2019 ($MILLION) 120
TABLE 80 AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS, & JOINT VENTURES, 2010–2014 124
TABLE 81 EXPANSIONS, 2010–2014 125
TABLE 82 NEW PRODUCT LAUNCHES, 2010–2014 126
TABLE 83 MERGERS & ACQUISITIONS, 2010–2014 127
TABLE 84 OTHER DEVELOPMENTS, 2010–2014 128


LIST OF FIGURES

FIGURE 1 RESEARCH METHODOLOGY 21
FIGURE 2 BOTTOM-UP APPROACH 23
FIGURE 3 TOP-DOWN APPROACH 23
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY, DESIGNATION, AND REGION 24
FIGURE 5 OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SERVICES MARKET SNAPSHOT (2014 VS. 2019): SYNTHESIZED OLIGONUCLEOTIDES ARE THE NEW REVENUE POCKETS 27
FIGURE 6 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE, BY APPLICATION, 2014 28
FIGURE 7 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY GEOGRAPHY, 2014 29
FIGURE 8 ATTRACTIVE MARKET OPPORTUNITIES IN THE SYNTHESIZED OLIGONUCLEOTIDES MARKET 30
FIGURE 9 SYNTHESIZED OLIGONUCLEOTIDES MARKET IN THE ASIA-PACIFIC REGION (2013) 31
FIGURE 10 U.S. COMMANDS NEARLY HALF OF THE MARKET SHARE 32
FIGURE 11 NORTH AMERICA AND ASIA-PACIFIC TO WITNESS SIGNIFICANT GROWTH IN THE FORECAST PERIOD 32
FIGURE 12 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MARKET: PCR SEGMENT (2019) 33
FIGURE 13 SIGNIFICANT CONTRIBUTION OF SYNTHESIZED OLIGONUCLEOTIDES TO THE TOTAL MARKET GROWTH FROM 2014–2019 34
FIGURE 14 APAC MARKET TO DRIVE THE MARKET GROWTH DURING THE FORECAST PERIOD 35
FIGURE 15 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION, BY PRODUCTS & SERVICES 37
FIGURE 16 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION, BY APPLICATION 38
FIGURE 17 OLIGONUCLEOTIDE SYNTHESIS MARKET SEGMENTATION, BY END USER 38
FIGURE 18 EMERGING APPLICATIONS IN MOLECULAR DIAGNOSTICS AND THERAPEUTICS FIELDS WILL SPUR THE DEMAND FOR OLIGONUCLEOTIDE SYNTHESIS 39
FIGURE 19 INDUSTRY TRENDS 49
FIGURE 20 COST PRESSURE AFFECTING THE INDUSTRY GROWTH 50
FIGURE 21 DISTRIBUTION IS THE PREFERRED STRATEGY FOLLOWED BY OLIGONUCLEOTIDE MANUFACTURERS 54
FIGURE 22 GROWING DEMAND FOR OLIGOS IN PERSONALIZED MEDICINE, COMPANION DIAGNOSTICS, & MOLECULAR DIAGNOSTICS TO BOOST THE OLIGONUCLEOTIDE SYNTHESIS MARKET 56
FIGURE 23 SYNTHESIZED OLIGONUCLEOTIDES COMMAND THE LARGEST SHARE OF THE MARKET 57
FIGURE 24 PRIMERS WILL CONTINUE TO DOMINATE THE SYNTHESIZED OLIGONUCLEOTIDES MARKET WITH AROUND 50% SHARE IN 2019 60
FIGURE 25 INTERMEDIATE-SCALE SYNTHESIS OLIGOS TO WITNESS DOUBLE-DIGIT MARKET GROWTH ACROSS ALL GEOGRAPHIES 64
FIGURE 26 CUSTOM OLIGOS WILL CONTINUE TO DOMINATE THE SYNTHESIZED OLIGONUCLEOTIDES MARKET WITH A SHARE OF MORE THAN 80% IN 2019 65
FIGURE 27 REAGENTS MARKET IN APAC IS EXPECTED TO GROW AT A DOUBLE-DIGIT CAGR DUE TO RISING DEMAND FOR SYNTHESIZED OLIGOS 68
FIGURE 28 ROBUST DEMAND FROM CHINA IS FUELING THE GROWTH OF THE GLOBAL OLIGONUCLEOTIDE SYNTHESIS EQUIPMENT MARKET 70
FIGURE 29 DIAGNOSTIC AND THERAPEUTIC APPLICATIONS MARKETS EXPECTED TO GROW AT DOUBLE-DIGIT CAGR 73
FIGURE 30 RESEARCH APPLICATION MARKET TO REACH ONE BILLION BY 2019 74
FIGURE 31 SEQUENCING IS THE FASTEST-GROWING SEGMENT IN THE RESEARCH APPLICATIONS MARKET 75
FIGURE 32 RNAI SEGMENT IS EXPECTED TO BOOST THE GROWTH OF THE THERAPEUTIC APPLICATIONS MARKET 84
FIGURE 33 BROAD END-USER BASE OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS & SERVICES 90
FIGURE 34 THE DIAGNOSTIC LABORATORIES END-USER MARKET IS EXPECTED TO DOUBLE
BY 2019 91
FIGURE 35 ACADEMIC RESEARCH INSTITUTES SEGMENT TO WITNESS THE HIGHEST GROWTH RATE IN THE APAC REGION 92
FIGURE 36 THE DIAGNOSTIC LABORATORIES END-USER SEGMENT TO WITNESS DOUBLE-DIGIT GROWTH ACROSS ALL GEOGRAPHIES 93
FIGURE 37 GEOGRAPHIC SNAPSHOT (2014): RAPID GROWTH MARKETS ARE EMERGING AS NEW HOT SPOTS 97
FIGURE 38 NORTH AMERICAN MARKET SNAPSHOT: DEMAND WILL BE DRIVEN BY DEVELOPMENTS IN THE U.S. BIOTECHNOLOGY INDUSTRY AND THE INCREASING USAGE OF OLIGONUCLEOTIDES IN THE MOLECULAR DIAGNOSTICS AND THERAPEUTICS ARENA 99
FIGURE 39 APAC: AN ATTRACTIVE DESTINATION FOR ALL PRODUCTS & SERVICES CATEGORIES 110
FIGURE 40 COMPANIES ADOPTED AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, CONTRACTS, AND JOINT VENTURES AS THE KEY GROWTH STRATEGY OVER THE LAST FOUR YEARS 121
FIGURE 41 BATTLE FOR MARKET SHARE: AGREEMENTS, PARTNERSHIPS, COLLABORATIONS, AND JOINT VENTURES WAS THE KEY STRATEGY 122
FIGURE 42 GLOBAL OLIGONUCLEOTIDE SYNTHESIS MOST ACTIVE MARKET PLAYER (ON THE BASIS OF RECENT DEVELOPMENTS), 2010–2014 123


【レポートのキーワード】

オリゴヌクレオチド合成、オリゴヌクレオチド合成装置、オリゴ合成サービス、合成用試薬、カスタムオリゴ、DNA合成

★調査レポート[世界のオリゴヌクレオチド合成市場:オリゴ合成装置、試薬、サービス] ( Oligonucleotide Synthesis Market by Product & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical & Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global Forecast to 2019 / MAM-BT-2680) 販売に関する免責事項
[世界のオリゴヌクレオチド合成市場:オリゴ合成装置、試薬、サービス] ( Oligonucleotide Synthesis Market by Product & Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, Pharmaceutical & Biotechnology), Application (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) - Global Forecast to 2019 / MAM-BT-2680) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆